Agape ATP (ATPC) Competitors

Agape ATP (NASDAQ:ATPC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Does the media refer more to ATPC or XGN?

In the previous week, Agape ATP had 3 more articles in the media than Exagen. MarketBeat recorded 5 mentions for Agape ATP and 2 mentions for Exagen. Exagen's average media sentiment score of 1.77 beat Agape ATP's score of 0.96 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agape ATP	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, ATPC or XGN?

Agape ATP has a beta of -0.97, meaning that its share price is 197% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Is ATPC or XGN more profitable?

Exagen has a net margin of -28.85% compared to Agape ATP's net margin of -183.13%. Agape ATP's return on equity of -20.32% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agape ATP	-183.13%	-20.32%	-18.55%
Exagen	-28.85%	-130.38%	-34.69%

Do institutionals and insiders hold more shares of ATPC or XGN?

0.0% of Agape ATP shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 9.7% of Agape ATP shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend ATPC or XGN?

Exagen has a consensus target price of $11.25, suggesting a potential upside of 15.50%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Agape ATP.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agape ATP	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exagen	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, ATPC or XGN?

Agape ATP has higher earnings, but lower revenue than Exagen. Exagen is trading at a lower price-to-earnings ratio than Agape ATP, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agape ATP	$1.32M	50.96	-$2.47M	-$0.41	-3.28
Exagen	$55.64M	3.85	-$15.11M	-$0.89	-10.94

Summary

Exagen beats Agape ATP on 9 of the 16 factors compared between the two stocks.